三级中心21例利妥昔单抗相关新发结肠炎
本文报告了三级中心21例利妥昔单抗相关新发结肠炎患者,旨在识别此类患者并更好描述其临床特征和病程。据作者所知,此前尚无利妥昔单抗治疗相关显微镜性结肠炎的报道。
要点
- 利妥昔单抗与多种胃肠道不良反应相关,包括腹泻和肠穿孔。
- 近期报告将利妥昔单抗与新发炎症性肠病相关联。
- 据作者所知,此前无利妥昔单抗相关显微镜性结肠炎的报道。
核心结论
- 本文旨在识别利妥昔单抗相关结肠炎患者,并更好描述其临床特征和病程。
研究设计与样本
- 三级中心21例利妥昔单抗相关新发结肠炎患者。
主要发现
- 原文未报告具体 findings。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes, is commonly used in the treatment of hematologic malignancies and rheumatologic disorders.1,2 It acts to rapidly deplete the B lymphocyte population through multiple mechanisms, leading to dysregulation of the immune system.3 Rituximab has been associated with numerous adverse gastrointestinal effects including diarrhea and bowel perforation, and recent reports have associated rituximab with the development of de novo inflammatory bowel disease (IBD).4,5 To our knowledge, there have been no reports of microscopic colitis (MC) associated with rituximab therapy. We aimed to identify patients with rituximab-associated colitis, and to better characterize the clinical features and disease course of these patients.
引用
- Eckmann JD, Chedid V, Quinn KP, et al. De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center. Clin Gastroenterol Hepatol. 2019. PMID: 30905719. doi:10.1016/j.cgh.2019.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。